Feds, J&J Agree to $2.2 Bil. Settlement in Risperdal Suit

, The Legal Intelligencer


Subsidiaries of Johnson & Johnson have agreed to pay $2.2 billion to resolve a suit involving, among other things, the marketing for off-label use of the antipsychotic drug Risperdal.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1383573634371

Thank you!

This article's comments will be reviewed.